Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products

Journal of the Neurological Sciences

Volumn 361, Issue , 2016, Pages 256-271

  Awasthi, Manika ^a   Singh, Swati ^a   Pandey, Veda P ^a   Dwivedi, Upendra N ^a  

^a UNIVERSITY OF LUCKNOW   (India)

Author keywords

3D QSAR; Alzheimer's disease; Amyloid beta; Molecular docking and dynamics simulation; Resveratrol; Terpenoids

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; ALPHA SECRETASE; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE INHIBITOR; CHOLESTEROL; GAMMA SECRETASE INHIBITOR; NATURAL PRODUCT; VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CELL DEATH; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; DEMENTIA; DRUG DESIGN; HOMEOSTASIS; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PALLIATIVE THERAPY; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; STRUCTURE ACTIVITY RELATION; BRAIN; COMPUTER SIMULATION; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COMPUTER SIMULATION; HUMANS;

EID: 84959010623     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2016.01.008     Document Type: Review

References (170)

1. P.A. Adlard, R.A. Cherny, D.I. Finkelstein, E. Gautier, E. Robb, M. Cortes, I. Volitakis, X. Liu, J.P. Smith, K. Perez, K. Laughton, Q.X. Li, S.A. Charman, J.A. Nicolazzo, S. Wilkins, K. Deleva, T. Lynch, G. Kok, C.W. Ritchie, R.E. Tanzi, R. Cappai, C.L. Masters, K.J. Barnham, and A.I. Bush Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta Neuron 59 2008 43 55
2. P.S. Aisen, D. Saumier, R. Briand, J. Laurin, F. Gervais, P. Tremblay, and D. Garceau Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease Neurology 67 2006 1757 1763
3. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, A. Gamst, D.M. Holtzman, W.J. Jagust, R.C. Petersen, P.J. Snyder, M.C. Carrillo, B. Thies, and C.H. Phelps The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 270 279
4. T. Alkam, A. Nitta, H. Mizoguchi, A. Itoh, and T. Nabeshima A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta (25-35) Behav. Brain Res. 180 2007 139 145
5. Alzheimer's Association Alzheimer's disease facts and figures Alzheimers Dement. 10 2014 (http://www.alz.org/downloads/Facts-Figures-2014.pdf)
6. R. Anand, K.D. Gill, and A.A. Mahdi Therapeutics of Alzheimer's disease: past, present and future Neuropharmacology 76 2014 27 50
7. M.A. Ansari, H.M. Abdul, G. Joshi, W.O. Opii, and D.A. Butterfield Protective effect of quercetin in primary neurons against Abeta (1-42): relevance to Alzheimer's disease J. Nutr. Biochem. 20 2009 269 275
8. S. Asadi, A. Ahmadiani, M.A. Esmaeili, A. Sonboli, N. Ansari, and F. Khodagholi In vitro antioxidant activities and an investigation of neuroprotection by six Salvia species from Iran: a comparative study Food Chem. Toxicol. 48 2010 1341 1349
9. K.R. Bales, T. Verina, R.C. Dodel, Y. Du, L. Altstiel, M. Bender, P. Hyslop, E.M. Johnstone, S.P. Little, D.J. Cummins, P. Piccardo, B. Ghetti, and S.M. Paul Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition Nat. Genet. 17 1997 263 264
10. C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, and E. Jones Alzheimer's disease Lancet 377 2011 1019 1031
11. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk, and T. Yednock Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 2000 916 919
12. R.J. Bateman, E.R. Siemers, K.G. Mawuenyega, G. Wen, K.R. Browning, W.C. Sigurdson, K.E. Yarasheski, S.W. Friedrich, R.B. Demattos, P.C. May, S.M. Paul, and D.M. Holtzman A γ-secretase inhibitor decreases amyloid-β production in the central nervous system Ann. Neurol. 66 2009 48 54
13. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, N.C. Fox, D.S. Marcus, N.J. Cairns, X. Xie, T.M. Blazey, D.M. Holtzman, A. Santacruz, V. Buckles, A. Oliver, K. Moulder, P.S. Aisen, B. Ghetti, W.E. Klunk, E. McDade, R.N. Martins, C.L. Masters, R. Mayeux, J.M. Ringman, M.N. Rossor, P.R. Schofield, R.A. Sperling, S. Salloway, and J.C. Morris Clinical and biomarker changes in dominantly inherited Alzheimer's disease N. Engl. J. Med. 367 2012 795 804
14. L.M. Bekris, C.E. Yu, T.D. Bird, and D.W. Tsuang Genetics of Alzheimer disease J. Geriatr. Psychiatry Neurol. 23 2010 213 227
15. T.L. Benzinger, T. Blazey, C.R. Jack Jr., R.A. Koeppe, Y. Su, C. Xiong, M.E. Raichle, A.Z. Snyder, B.M. Ances, and R.J. Bateman Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 110 2013 E4502 E4509
16. G. Bitan, E.A. Fradinger, S.M. Spring, and D.B. Teplow Neurotoxic protein oligomers: what you see is not always what you get Amyloid 12 2005 88 95
17. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol. 2 2003 605 613
18. M. Boada, E. Ramos-Fernández, B. Guivernau, F.J. Muñoz, M. Costa, A.M. Ortiz, J.I. Jorquera, L. Núñez, M. Torres, and A. Páez Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: rationale and treatment approach of the AMBAR (Alzheimer Management by Albumin Replacement) study Neurologia 9 2014 30 39
19. B. Bohrmann, K. Baumann, J. Benz, F. Gerber, W. Huber, F. Knoflach, J. Messer, K. Oroszlan, R. Rauchenberger, W.F. Richter, C. Rothe, M. Urban, M. Bardroff, M. Winter, C. Nordstedt, and H. Loetscher Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-beta J. Alzheimers Dis. 28 2012 49 69
20. J.C. Breitner, B.W. Wyse, J.C. Anthony, K.A. Welsh-Bohmer, D.C. Steffens, M.C. Norton, J.T. Tschanz, B.L. Plassman, M.R. Meyer, I. Skoog, and A. Khachaturian APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the cache county study Neurology 53 1999 321 331
21. V.P. Bulgakov, Y.V. Inyushkina, and S.A. Fedoreyev Rosmarinic acid and its derivatives: biotechnology and applications Crit. Rev. Biotechnol. 32 2012 203 217
22. R. Bullock Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date Alzheimer Dis. Assoc. Disord. 20 2006 23 29
23. D. Burdick, J. Kosmoski, M.F. Knauer, and C.G. Glabe Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, Abeta1-42, in differentiated PC12 cells Brain Res. 746 1997 275 284
24. A.H. Burstein, Q. Zhao, J. Ross, S. Styren, J.W. Landen, W.W. Ma, F. McCush, C. Alvey, J.W. Kupiec, and M.M. Bednar Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease Clin. Neuropharmacol. 36 2013 8 13
25. J. Busciglio, D.H. Gabuzda, P. Matsudaira, and B.A. Yankner Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells Proc. Natl. Acad. Sci. U. S. A. 90 1993 2092 2096
26. A.I. Bush, W.H. Pettingell, G. Multhaup, M. d Paradis, J.P. Vonsattel, J.F. Gusella, K. Beyreuther, C.L. Masters, and R.E. Tanzi Rapid induction of Alzheimer Aβ amyloid formation by zinc Science 265 1994 1464 1467
27. I. Caesar, M. Jonson, K.P. Nilsson, S. Thor, and P. Hammarström Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila PLoS One 7 2012 314 324
28. F.A. Caetano, F.H. Beraldo, G.N. Hajj, A.L. Guimaraes, S. Jürgensen, A.P. Wasilewska-Sampaio, P.H. Hirata, I. Souza, C.F. Machado, D.Y. Wong, F.G. De Felice, S.T. Ferreira, V.F. Prado, R.J. Rylett, V.R. Martins, and M.A. Prado Amyloid-beta oligomers increase the localization of prion protein at the cell surface J. Neurochem. 117 2011 538 553
29. M. Calamai, F. Chiti, and C.M. Dobson Amyloid fibril formation can proceed from different conformations of a partially unfolded protein Biophys. J. 89 2005 4201 4210
30. M. Chen, N.C. Inestrosa, G.S. Ross, and H.L. Fernandez Platelets are the primary source of amyloid beta-peptide in human blood Biochem. Biophys. Res. Commun. 213 1995 96 103
31. R.A. Cherny, C.S. Atwood, M.E. Xilinas, D.N. Gray, W.D. Jones, C.A. McLean, K.J. Barnham, I. Volitakis, F.W. Fraser, Y. Kim, X. Huang, L.E. Goldstein, R.D. Moir, J.T. Lim, K. Beyreuther, H. Zheng, R.E. Tanzi, C.L. Masters, and A.I. Bush Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 30 2001 665 676
32. K. Chopra, S. Misra, and A. Kuhad Current perspectives on pharmacotherapy of Alzheimer's disease Expert. Opin. Pharmacother. 12 2011 335 350
33. V. Coric, C.H. van Dyck, S. Salloway, N. Andreasen, M. Brody, R.W. Richter, H. Soininen, S. Thein, T. Shiovitz, G. Pilcher, S. Colby, L. Rollin, R. Dockens, C. Pachai, E. Portelius, U. Andreasson, K. Blennow, H. Soares, C. Albright, H.H. Feldman, and R.M. Berman Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease Arch. Neurol. 13 2012 1 12
34. R.F. Cowburn, B. Wiehager, E. Trief, M. Li-Li, and E. Sundstrom Effects of beta-amyloid-(25-35) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor Neurochem. Res. 22 1997 1437 1442
35. C.J. Crump, S.V. Castro, F. Wang, N. Pozdnyakov, T.E. Ballard, S.S. Sisodia, K.R. Bales, S.D. Johnson, and Y.M. Li BMS-708, 163 targets presenilin and lacks notch-sparing activity Biochemistry 51 2012 7209 7211
36. B. Darocha-Souto, T.C. Scotton, M. Coma, A. Serrano-Pozo, T. Hashimoto, L. Serenó, M. Rodríguez, B. Sánchez, B.T. Hyman, and T. Gómez-Isla Brain oligomeric β-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice J. Neuropathol. Exp. Neurol. 70 2011 360 376
37. K.A. DaSilva, J.E. Shaw, and J. McLAurin Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention Exp. Neurol. 223 2010 311 321
38. M.L. Daviglus, C.C. Bell, W. Berrettini, P.E. Bowen, E.S. Connolly Jr., N.J. Cox, J.M. Dunbar-Jacob, E.C. Granieri, G. Hunt, K. McGarry, D. Patel, A.L. Potosky, E. Sanders-Bush, D. Silberberg, and M. Trevisan NIH state-of-the-science conference statement: preventing Alzheimer's disease and cognitive decline NIH Consens. State Sci. Statements 27 2010 1 30
39. R. Deane, S. Du Yan, R.K. Submamaryan, B. LaRue, S. Jovanovic, E. Hogg, D. Welch, L. Manness, C. Lin, J. Yu, H. Zhu, J. Ghiso, B. Frangione, A. Stern, A.M. Schmidt, D.L. Armstrong, B. Arnold, B. Liliensiek, P. Nawroth, F. Hofman, M. Kindy, D. Stern, and B. Zlokovic RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain Nat. Med. 9 2003 907 913
40. H. Decker, S. Jurgensen, M.F. Adrover, J. Brito-Moreira, T.R. Bomfim, W.L. Klein, A.L. Epstein, F.G. De Felice, D. Jerusalinsky, and S.T. Ferreira N-Methyl-d-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-beta peptide oligomers J. Neurochem. 115 2010 1520 1529
41. L. Desire, M. Marcade, H. Peillon, D. Drouin, and O. Sol Clinical trials of EHT0202, a neuroprotective and procognitive alpha-secretase Alzheimers Dement. 5 2009 255 256
42. R.S. Doody, R. Raman, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, K. Kieburtz, F. He, X. Sun, R.G. Thomas, P.S. Aisen, E. Siemers, G. Sethuraman, and R. Mohs A phase 3 trial of semagacestat for treatment of Alzheimer's disease N. Engl. J. Med. 369 2013 341 350
43. S.S. Durairajan, L.F. Liu, J.H. Lu, L.L. Chen, Q. Yuan, S.K. Chung, L. Huang, X.S. Li, J.D. Huang, and M. Li Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model Neurobiol. Aging 33 2012 2903 2919
44. T.K. Eom, B. Ryu, J.K. Lee, H.G. Byun, S.J. Park, and S.K. Kim β-secretase inhibitory activity of phenolic acid conjugated chitooligosaccharides J. Enzyme Inhib. Med. Chem. 28 2012 214 217
45. R. Etcheberrigaray, M. Tan, I. Dewachtert, C. Kuipéri, I. Van der Auwera, S. Wera, L. Qiao, B. Bank, T.J. Nelson, A.P. Kozikowski, F. Van Leuven, and D.L. Alkon Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice Proc. Natl. Acad. Sci. U. S. A. 101 2004 11141 11146
46. H.H. Feldman, R.S. Doody, M. Kivipelto, D.L. Sparks, D.D. Waters, R.W. Jones, E. Schwam, R. Schindler, J. Hey-Hadavi, D.A. DeMicco, and A. Breazna Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe Neurology 74 2010 956 964
47. A.S. Fleisher, R. Raman, E.R. Siemers, L. Becerra, C.M. Clark, R.A. Dean, M.R. Farlow, J.E. Galvin, E.R. Peskind, J.F. Quinn, A. Sherzai, B.B. Sowell, P.S. Aisen, and L.J. Thal Phase 2 safety trial targeting amyloid-β production with a γ-secretase inhibitor in Alzheimer disease Arch. Neurol. 65 2008 1031 1038
48. A.S. Fleisher, K. Chen, Y.T. Quiroz, L.J. Jakimovich, M.G. Gomez, C.M. Langois, J.B. Langbaum, N. Ayutyanont, A. Roontiva, P. Thiyyagura, W. Lee, H. Mo, L. Lopez, S. Moreno, N. Acosta-Baena, M. Giraldo, G. Garcia, R.A. Reiman, M.J. Huentelman, K.S. Kosik, P.N. Tariot, F. Lopera, and E.M. Reiman Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross sectional study Lancet Neurol. 11 2012 1057 1065
49. J. Freiherr, M. Hallschmid, W.H. Frey, Y.F. Brunner, C.D. Chapman, C. Holscher, S. Craft, F.G. De Felice, and C. Benedict Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence CNS Drugs 27 2013 505 514
50. J.F. Ge, J.P. Qiao, C.C. Qi, C.W. Wang, and J.N. Zhou The binding of resveratrol to monomer and fibril amyloid beta Neurochem. Int. 61 2012 1192 1201
51. D.S. Geldmacher, T. Fritsch, M.J. McClendon, and G. Landreth A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease Arch. Neurol. 68 2011 45 50
52. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, E.A. Swabb, and K.H. Zavitz Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial J. Am. Med. Assoc. 302 2009 2557 2564
53. H. Grossman, G. Marzloff, X. Luo, D. LeRoith, M. Sano, and G. Pasinetti NIC5-15 as a treatment for Alzheimer's: safety, pharmacokinetics and clinical variables Alzheimers Dement. 5 2009 259
54. J. Grutzendler, and J.C. Morris Cholinesterase inhibitors for Alzheimer's disease Drugs 61 2001 41 52
55. C. Haass, and B. De Strooper The presenilins in Alzheimer's disease-proteolysis holds the key Science 286 1999 916 919
56. C. Haass, A.Y. Hung, and D.J. Selkoe Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion J. Neurosci. 11 1991 3783 3793
57. C. Haass, M.G. Schlossmacher, A.Y. Hung, C. Vigo-Pelfrey, A. Mellon, B.L. Ostaszewski, I. Lieberburg, E.H. Koo, D. Schenk, and D.B. Teplow Amyloid beta-peptide is produced by cultured cells during normal metabolism Nature 359 1992 322 325
58. H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, J. Hardy, K. Herholz, A.L.W. Bokde, F. Jessen, Y.C. Hoessler, W.R. Sanhai, H. Zetterberg, J. Woodcock, and K. Blennow Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat. Rev. Drug Discov. 9 2010 560 574
59. J.Y. Han, and S.H. Han Primary prevention of Alzheimer's disease: is it an attainable goal? J. Korean Med. Sci. 29 2014 886 892
60. J. Hardy, K. Duff, K. Hardy, J. Perez-Tur, and M. Hutton Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau Nat. Neurosci. 1 1998 355 358
61. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
62. D.B. Henley, P.C. May, R.A. Dean, and E.R. Siemers Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease Expert. Opin. Pharmacother. 10 2009 1657 1664
63. D.R. Howlett, A.R. George, D.E. Owen, R.V. Ward, and R.E. Markwell Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer β-amyloid fibril formation Biochem. J. 343 1999 419 423
64. M. Hutton, C.L. Lendon, P. Rizzu, M. Baker, S. Froelich, H. Houlden, S. Pickering-Brown, S. Chakraverty, A. Isaacs, A. Grover, J. Hackett, J. Adamson, S. Lincoln, D. Dickson, P. Davies, R.C. Petersen, M. Stevens, E. de Graaff, E. Wauters, J. van Baren, M. Hillebrand, M. Joosse, J.M. Kwon, P. Nowotny, L.K. Che, J. Norton, J.C. Morris, L.A. Reed, J. Trojanowski, H. Basun, L. Lannfelt, M. Neystat, S. Fahn, F. Dark, T. Tannenberg, P.R. Dodd, N. Hayward, J.B. Kwok, P.R. Schofield, A. Andreadis, J. Snowden, D. Craufurd, D. Neary, F. Owen, B.A. Oostra, J. Hardy, A. Goate, J. van Swieten, D. Mann, T. Lynch, and P. Heutink Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 Nature 393 1998 702 705
65. B. Imbimbo Therapeutic potential of γ-secretase inhibitors and modulators Curr. Top. Med. Chem. 8 2008 54 61
66. B.P. Imbimbo Why did tarenflurbil fail in Alzheimer's disease? J. Alzheimers Dis. 17 2009 757 760
67. B.P. Imbimbo, E. Frigerio, M. Breda, F. Fiorentini, M. Fernandez, S. Sivilia, L. Giardino, L. Calzà, D. Norris, D. Casula, and M. Shenouda Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects Alzheimer Dis. Assoc. Disord. 27 2012 278 286
68. P.T. Jantzen, K.E. Connor, G. DiCarlo, G.L. Wenk, J.L. Wallace, A.M. Rojiani, D. Coppola, D. Morgan, and M.N. Gordon Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice J. Neurosci. 22 2002 2246 2254
69. Q. Jia, Y. Deng, and H. Qing Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials Biomed Res. Int. 2014 22
70. K. Jiménez-Aliaga, P. Bermejo-Bescós, J. Benedí, and S. Martín-Aragón Quercetin and rutin exhibit anti amyloidogenic and fibril disaggregating effects in vitro and potent antioxidant activity in APPswe cells Life Sci. 89 2011 939 945
71. R.N. Kalaria, G.E. Maestre, R. Arizaga, R.P. Friedland, D. Galasko, K. Hall, J.A. Luchsinger, A. Ogunniyi, E.K. Perry, F. Potocnik, M. Prince, R. Stewart, A. Wimo, Z.X. Zhang, and P. Antuono Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors Lancet Neurol. 7 2008 812 826
72. F. Khodagholi, B. Eftekharzadeh, N. Maghsoudi, and P.F. Rezaei Chitosan prevents oxidative stress-induced amyloid beta formation and cytotoxicity in NT2 neurons: involvement of transcription factors Nrf2 and NF-kappaB Mol. Cell. Biochem. 337 2010 39 51
73. I. Klyubin, D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, V. Betts, E.T. Spooner, L. Jiang, R. Anwyl, D.J. Selkoe, and M.J. Rowan Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo Nat. Med. 11 2005 556 561
74. D. Kobayashi, M. Zeller, T. Cole, M. Buttini, L. McConlogue, S. Sinha, S. Freedman, R.G. Morris, and K.S. Chen BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease Neurobiol. Aging 29 2008 861 873
75. A. Kowalska The beta-amyloid cascade hypothesis: a sequence of events leading to neurodegeneration in Alzheimer's disease Neurol. Neurochir. Pol. 38 2004 405 411
76. A.Y. Lai, and J. McLaurin Mechanisms of amyloid-beta peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins Int. J. Alzheimers Dis. 2011 2010 548380
77. R. Lai, B. Albala, J.M. Kaplow, J. Aluri, M. Yen, and A. Satlin First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing Alzheimers Dement. 8 2012 96
78. J.W. Landen, Q. Zhao, S. Cohen, M. Borrie, M. Woodward, C.B. Billing Jr., K. Bales, C. Alvey, F. McCush, J. Yang, J.W. Kupiec, and M.M. Bednar Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study Clin. Neuropharmacol. 36 2013 14 23
79. G. Landreth, Q. Jiang, S. Mandrekar, and M. Heneka PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease Neurotherapeutics 5 2008 481 489
80. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, J. Harrison, C.L. Masters, S. Targum, A.I. Bush, R. Murdoch, J. Wilson, and C.W. Ritchie Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 7 2008 779 786
81. L. Lannfelt, C. Möller, H. Basun, G. Osswald, D. Sehlin, A. Satlin, V. Logovinsky, and P. Gellerfors Perspectives on future Alzheimer therapies: amyloid-β protofibrils-a new target for immunotherapy with BAN2401 in Alzheimer's disease Alzheimers Res. Ther. 6 2014 16
82. Y.J. Lee, D.Y. Choi, Y.P. Yun, S.B. Han, K.W. Oh, and J.T. Hong Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its antineuroinflammatory properties J. Nutr. Biochem. 24 2012 298 310
83. C.A. Lemere Immunotherapy for Alzheimer's disease: hoops and hurdles Mol. Neurodegener. 8 2013 36
84. J. Lewis, D.W. Dickson, W.L. Lin, L. Chisholm, A. Corral, G. Jones, S.H. Yen, N. Sahara, L. Skipper, D. Yager, C. Eckman, J. Hardy, M. Hutton, and E. McGowan Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP Science 293 2001 1487 1491
85. F. Li, Q. Gong, H. Dong, and J. Shi Resveratrol, a neuroprotective supplement for Alzheimer's disease Curr. Pharm. Des. 18 2012 27 33
86. R. Li, Y.G. Huang, D. Fang, and W.D. Le (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury J. Neurosci. Res. 78 2004 723 731
87. R. Liu, F. Meng, L. Zhang, A. Liu, H. Qin, X. Lan, L. Li, and G. Du Luteolin isolated from the medicinal plant Elsholtzia rugulosa (Labiatae) prevents copper-mediated toxicity in β-amyloid precursor protein Swedish mutation overexpressing SH-SY5Y cells Molecules 16 2011 2084 2096
88. A. Lleo, S.M. Greenberg, and J.H. Growdon Current pharmacotherapy for Alzheimer's disease Annu. Rev. Med. 57 2006 513 533
89. M. Lorenzi, M. Donohue, D. Paternico, C. Scarpazza, S. Ostrowitzki, O. Blin, E. Irving, and G.B. Frisoni Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment Neurobiol. Aging 31 2010 1443 1451
90. Y. Luo, B. Bolon, S. Kahn, B.D. Bennett, S. Babu-Khan, P. Denis, W. Fan, H. Kha, J. Zhang, Y. Gong, L. Martin, J.C. Louis, Q. Yan, W.G. Richards, M. Citron, and R. Vassar Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation Nat. Neurosci. 4 2001 231 232
91. S. Madhusudan, A. Protheroe, D. Propper, C. Han, P. Corrie, H. Earl, B. Hancock, P. Vasey, A. Turner, F. Balkwill, S. Hoare, and A.L. Harris A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer Br. J. Cancer 89 2003 1418 1422
92. I. Maillard, S.H. Adler, and W.S. Pear Notch and the immune system Immunity 19 2003 781 791
93. S.A. Mandel, T. Amit, L. Kalfon, L. Reznichenko, O. Weinreb, and M.B.H. Youdim Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG) J. Alzheimers Dis. 15 2008 211 222
94. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto Alzheimer's disease: clinical trials and drug development Lancet Neurol. 9 2010 702 716
95. M. Marcade, J. Bourdin, N. Loiseau, H. Peillon, A. Rayer, D. Drouin, F. Schweighoffer, and L. Désiré Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing J. Neurochem. 106 2008 392 404
96. R.L. Martone, H. Zhou, K. Atchison, T. Comery, J.Z. Xu, X. Huang, X. Gong, M. Jin, A. Kreft, B. Harrison, S.C. Mayer, S. Aschmies, C. Gonzales, M.M. Zaleska, D.R. Riddell, E. Wagner, P. Lu, S.C. Sun, J. Sonnenberg-Reines, A. Oganesian, K. Adkins, M.W. Leach, D.W. Clarke, D. Huryn, M. Abou-Gharbia, R. Magolda, J. Bard, G. Frick, S. Raje, S.B. Forlow, C. Balliet, M.E. Burczynski, P.H. Reinhart, H.I. Wan, M.N. Pangalos, and J.S. Jacobsen Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer's disease J. Pharmacol. Exp. Ther. 331 2009 598 608
97. C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald, and K. Beyreuther Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc. Natl. Acad. Sci. U. S. A. 82 1985 4245 4249
98. P.C. May, B.A. Willis, S.L. Lowe, R.A. Dean, S.A. Monk, P.J. Cocke, J.E. Audia, L.N. Boggs, A.R. Borders, R.A. Brier, D.O. Calligaro, T.A. Day, L. Ereshefsky, J.A. Erickson, H. Gevorkyan, C.R. Gonzales, D.E. James, S.S. Jhee, S.F. Komjathy, L. Li, T.D. Lindstrom, B.M. Mathes, F. Martényi, S.M. Sheehan, S.L. Stout, D.E. Timm, G.M. Vaught, B.M. Watson, L.L. Winneroski, Z. Yang, and D.J. Mergott The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans J. Neurosci. 35 2015 1199 1210
99. J.E. McElhaney, and R.B. Effros Immuno-senescence: what does it mean to health outcomes in older adults? Curr. Opin. Immunol. 21 2009 418 424
100. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack, C.H. Kawas, W.E. Klunk, W.J. Koroshetz, J.J. Manly, R. Mayeux, R.C. Mohs, J.C. Morris, M.N. Rossor, P. Scheltens, M.C. Carrillo, B. Thies, S. Weintraub, and C.H. Phelps The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 263 269
101. J. McLaurin, R. Golomb, A. Jurewicz, J.P. Antel, and P.E. Fraser Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Abeta-induced toxicity J. Biol. Chem. 275 2000 18495 18502
102. P.D. Mehta, T. Pirttila, B.A. Patrick, M. Barshatzky, and S.P. Mehta Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease Neurosci. Lett. 304 2001 102 106
103. G. Miller Stopping Alzheimer's before it starts Science 337 2012 790 792
104. A. Mohamed, and E. Posse de Chaves Aβ internalization by neurons and glia Int. J. Alzheimers Dis. 2011 2011 127984
105. H.J. Moller, and M.B. Graeber The case described by Alois Alzheimer in 1911 Eur. Arch. Psychiatry Clin. Neurosci. 248 1998 111 122
106. J. Moreth, C. Mavoungou, and K. Schindowski Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets? Immun. Ageing 10 2013 18
107. H. Naaz, S. Singh, V.P. Pandey, P. Singh, and U.N. Dwivedi Anti-cholinergic alkaloids as potential therapeutic agents for Alzheimer's disease: an in silico approach Ind. J. Biochem. Biophys. 50 2013 120 125
108. S. Nag, B. Sarkar, A. Bandyopadhyay, B. Sahoo, V.K. Sreenivasan, M. Kombrabail, C. Muralidharan, and S. Maiti Nature of the amyloid-β monomer and the monomer-oligomer equilibrium J. Biol. Chem. 286 2011 13827 13833
109. D.J. Newman, and G.M. Cragg Natural products as sources of new drugs over the 30 years from 1981 to 2010 J. Nat. Prod. 75 2012 311 335
110. M. Nicolas, A. Wolfer, K. Raj, J.A. Kummer, P. Mill, M. van Noort, C.C. Hui, H. Clevers, G.P. Dotto, and F. Radtke Notch1 functions as a tumor suppressor in mouse skin Nat. Genet. 33 2003 416 421
111. S. Oddo, L. Billings, J.P. Kesslak, D.H. Cribbs, and F.M. LaFerla Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome Neuron 43 2004 321 332
112. M. Ohno, E.A. Sametsky, L.H. Younkin, H. Oakley, S.G. Younkin, M. Citron, R. Vassar, and J.F. Disterhoft BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease Neuron 41 2004 27 33
113. J.A. Orellana, K.F. Shoji, V. Abudara, P. Ezan, E. Amigou, P.J. Sáez, J.X. Jiang, C.C. Naus, J.C. Sáez, and C. Giaume Amyloid β-induced death in neurons involves glial and neuronal hemichannels J. Neurosci. 31 2011 4962 4977
114. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B.F. Michel, M. Boada, A. Frank, and C. Hock Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization Neurology 61 2003 46 54
115. M. Pohanka Cholinesterases, a target of pharmacology and toxicology Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 155 2011 219 229
116. G. Poli, E. Corda, B. Lucchini, M. Puricelli, P.A. Martino, P. Dall'ara, G. Villetti, S.R. Bareggi, C. Corona, E.V. Costassa, P. Gazzuola, B. Iulini, M. Mazza, P. Acutis, P. Mantegazza, C. Casalone, and B.P. Imbimbo Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie Prion 6 2012 62 72
117. Y.T. Quiroz, A.E. Budson, K. Celone, A. Ruiz, R. Newmark, G. Castrillon, F. Lopera, and C.E. Stern Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease Ann. Neurol. 68 2010 865 875
118. Y.T. Quiroz, C.E. Stern, E.M. Reiman, M. Brickhouse, A. Ruiz, R.A. Sperling, F. Lopera, and B.C. Dickerson Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers J. Neurol. Neurosurg. Psychiatry 84 2013 556 561
119. L.M. Refolo, M.A. Pappolla, J. LaFrancois, B. Malester, S.D. Schmidt, T. Thomas-Bryant, G.S. Tint, R. Wang, M. Mercken, S.S. Petanceska, and K.E. Duff A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease Neurobiol. Dis. 8 2001 890 899
120. E.M. Reiman, B.S. Jessica, A.S. Langbaum, R.J. Fleisher, K.C. Caselli, N. Ayutyanont, Y.T. Quiroz, K.S. Kosik, F. Lopera, and P.N. Tariot Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments J. Alzheimers Dis. 26 2011 321 329
121. C. Reitz, C. Brayne, and R. Mayeux Epidemiology of Alzheimer disease Nat. Rev. Neurol. 7 2011 137 152
122. N.R. Relkin, P. Szabo, B. Adamiak, T. Burgut, C. Monthe, R.W. Lent, S. Younkin, L. Younkin, R. Schiff, and M.E. Weksler 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease Neurobiol. Aging 30 2009 1728 1736
123. R.G. Riekse, G. Li, E.C. Petrie, and et al. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid J. Alzheimers Dis. 10 2006 399 406
124. J. Rogers, S. Webster, L.F. Lue, L. Brachova, W.H. Civin, M. Emmerling, B. Shivers, D. Walker, and P. McGeer Inflammation and Alzheimer's disease pathogenesis Neurobiol. Aging 17 1996 681 686
125. K. Rogers, K.M. Felsenstein, L. Hrdlicka, Z. Tu, F. Albayya, W. Lee, S. Hopp, M.J. Miller, D. Spaulding, Z. Yang, H. Hodgdon, S. Nolan, M. Wen, D. Costa, J.F. Blain, E. Freeman, B. De Strooper, V. Vulsteke, L. Scrocchi, H. Zetterberg, E. Portelius, B. Hutter-Paier, D. Havas, M. Ahlijanian, D. Flood, L. Leventhal, G. Shapiro, H. Patzke, R. Chesworth, and G. Koenig Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice Mol. Neurodegener. 7 2012 61
126. A.E. Roher, K.C. Palmer, E.C. Yurewicz, M.J. Ball, and B.D. Greenberg Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue J. Neurochem. 61 1993 1916 1926
127. J.M. Ryan, and M. Grundman Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing J. Alzheimers Dis. 17 2009 243
128. M.N. Sabbagh, A. Agro, J. Bell, P.S. Aisen, E. Schweizer, and D. Galasko PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Dis. Assoc. Disord. 25 2011 206 212
129. B.M. Sahoo, S.C. Dinda, R. Kumar, and J.R. Panda Computational approaches for drug design and discovery process Curr. Pharma Res. 2 2012 600 611
130. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, M. Raskind, M. Sabbagh, L.S. Honig, R. Doody, C.H. van Dyck, R. Mulnard, J. Barakos, K.M. Gregg, E. Liu, I. Lieberburg, D. Schenk, R. Black, and M. Grundman A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
131. A. Sandberg, L.M. Luheshi, S. Sollvander, T. Pereira de Barros, B. Macao, T.P. Knowles, H. Biverstal, C. Lendel, F. Ekholm-Petterson, A. Dubnovitsky, L. Lannfelt, C.M. Dobson, and T. Härd Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering Proc. Natl. Acad. Sci. U. S. A. 107 2010 15595 15600
132. A. Sandebring, H. Welander, B. Winblad, C. Graff, and L.O. Tjernberg The pathogenic Aβ43 is enriched in familial and sporadic Alzheimer disease PLoS One 8 2013 e55847
133. M.J. Savage, G. Wu, A. McCampbell, K.R. Wessner, M. Citron, X. Liang, S. Hsieh, A.L. Wolfe, G.G. Kinney, L.B. Rosen, and J.J. Renger A novel multivalent Abeta peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of abeta peptide species Alzheimers Dement. 6 2010 142
134. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, and P. Seubert Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
135. A. Schmidt, S. Yan, S. Yan, and D. Stern The biology of the receptor for advanced glycation end products and its ligands Biochim. Biophys. Acta 1498 2000 99 111
136. A. Schneeberger, M. Mandler, O. Otava, W. Zauner, F. Mattner, and W. Schmidt Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing J. Nutr. Health Aging 13 2009 264 267
137. C. Shi, D.D. Zheng, F.M. Wu, J. Liu, and J. Xu The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3β pathway mediates bilobalide-induced reduction in amyloid β-peptide Neurochem. Res. 37 2012 298 306
138. S. Sivilia, L. Lorenzini, A. Giuliani, M. Gusciglio, M. Fernandez, V.A. Baldassarro, C. Mangano, L. Ferraro, V. Pietrini, M.F. Baroc, A.R. Viscomi, S. Ottonello, G. Villetti, B.P. Imbimbo, L. Calzà, and L. Giardino Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice BMC Neurosci. 14 2013 44
139. A.D. Smith, and K. Yaffe Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts J. Alzheimers Dis. 38 2014 699 703
140. D.L. Sparks, Y.M. Kuo, A. Roher, T. Martin, and R.J. Lukas Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations Ann. N. Y. Acad. Sci. 903 2000 335 344
141. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, T. Iwatsubo, C.R. Jack, J. Kaye, T.J. Montine, D.C. Park, E.M. Reiman, C.C. Rowe, E. Siemers, Y. Stern, K. Yaffe, M.C. Carrillo, B. Thies, M. Morrison-Bogorad, M.V. Wagster, and C.H. Phelps Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 280 292
142. B.Z. Stanger, R. Datar, L.C. Murtaugh, and D.A. Melton Direct regulation of intestinal fate by Notch Proc. Natl. Acad. Sci. U. S. A. 102 2005 12443 12448
143. Y. Sun, G. Zhang, C.A. Hawkes, J.E. Shaw, J. McLaurin, and M. Nitz Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation Bioorg. Med. Chem. 16 2008 7177 7184
144. M. Sunde, and C.C.F. Blake The structure of amyloid fibrils by electron microscopy and X-ray diffraction Adv. Protein Chem. 50 1997 123 159
145. R. Tamayev, S. Matsuda, M. Fa, O. Arancio, and L. D'Adamio Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits Proc. Natl. Acad. Sci. U. S. A. 107 2010 20822 20827
146. J.J.N. Tang Beta-secretase as target for amyloid-reduction therapy Alzheimers Dement. 5 2009 74
147. J. Tavakoli, S. Miar, M.M. Zadehzare, and H. Akbari Evaluation of effectiveness of herbal medication in cancer care: a review study Iran J. Cancer Prev. 5 2012 144 156
148. M. Tripathi, D. Vibha, P. Gupta, R. Bhatia, M.V. Srivastava, and S. Vivekanandhan Risk factors of dementia in north India: a case-control study Aging Ment. Health 16 2012 228 235
149. C.M. van Duijn, P. de Knijff, M. Cruts, A. Wehnert, L.M. Havekes, A. Hofman, and C. van Broeckhoven Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease Nat. Genet. 7 1994 74 78
150. R.J. van Marum Current and future therapy in Alzheimer's disease Fundam. Clin. Pharmacol. 22 2008 265 274
151. R. Vassar BACE1 inhibitor drugs in clinical trials for Alzheimer's disease Alzheimers Res. Ther. 6 2014 89
152. C. Veeresham Natural products derived from plants as a source of drugs J. Adv. Pharm. Technol. Res. 3 2012 200 201
153. S. Wahrle, P. Das, A.C. Nyborg, C. McLendon, M. Shoji, T. Kawarabayashi, L.H. Younkin, S.G. Younkin, and T.E. Golde Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains Neurobiol. Dis. 9 2002 11 23
154. D.M. Walsh, B.P. Tseng, R.E. Rydel, M.B. Podlisny, and D.J. Selkoe The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain Biochemistry 39 2000 10831 10839
155. C.Y. Wang, W. Zheng, T. Wang, J.W. Xie, S.L. Wang, B.L. Zhao, W.P. Teng, and Z.Y. Wang Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model Neuropsychopharmacology 36 2011 1073 1089
156. J. Wang, L. Ho, and G.M. Passinetti The developmentof NIC5-15, a natural anti-diabetic agent, in the treatment of Alzheimer's disease Alzheimers Dement. 1 2005 62
157. Y. Wang, C.L. Finstad, A.M. Walfield, C. Sia, K.K. Sokoll, T.Y. Chang, X.D. Fang, C.H. Hung, B. Hutter-Paier, and M. Windisch Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease Vaccine 25 2007 3041 3052
158. Y. Wang, X.C. Tang, and H.Y. Zhang Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice J. Neurosci. Res. 90 2012 508 517
159. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde, and E.H. Koo A subset of NSAIDs lower amyloidogenic βA42 independently of cyclooxygenase activity Nature 414 2001 212 216
160. K. Welsh-Bohmer, H. Romero, K. Hayden, B. Plassman, C. Germain, M. Sano, M. Espeland, S. Craft, A. Monsch, L. Schneider, C. Chiang, S. Haneline, J. Oneil, M. Malholtra, S. Brannan, D. Burns, and A.D. Roses Challenges in international clinical trials to delay early symptomatic Alzheimer's disease Alzheimers Dement. 9 2013 P137 P138
161. D.M. Wilcock, and C.A. Colton Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials J. Alzheimers Dis. 15 2008 555 569
162. D.M. Wilcock, N. Gharkholonarehe, W.E. VanNostrand, J. Davis, M.P. Vitek, and C.A. Colton Amyloid reduction by amyloid-β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease J. Neurosci. 29 2009 7957 7965
163. M. Willem, A.N. Garratt, B. Novak, M. Citron, S. Kaufmann, A. Rittger, B. DeStrooper, P. Saftig, C. Birchmeier, and C. Haass Control of peripheral nerve myelination by the β-secretase BACE1 Science 314 2006 664 666
164. B. Winblad, L. Minthon, and A. Floesser Results of the first-in-man study with the active Aβ immunotherapy CAD106 in Alzheimer patients Alzheimers Dement. 5 2009 113 114
165. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, and G. Siegel Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch. Neurol. 57 2000 1439 1443
166. Z. Xiong, Z. Hongmei, S. Lu, and L. Yu Curcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer's disease Pharmacol. Rep. 63 2011 1101 1108
167. Q. Yan, J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A.L. Biere, M. Citron, and G. Landreth Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease J. Neurosci. 20 2003 7504 7509
168. R. Yan, M.J. Blenkowski, M.E. Shuck, H. Miao, M.C. Tory, A.M. Pauley, J.R. Brashier, N.C. Stratman, W.R. Mathews, A.E. Buhl, D.B. Carter, A.G. Tomasselli, L.A. Parodi, R.L. Heinrikson, and M.E. Gurney Membrane anchored aspartyl protease with Alzheimer's disease β-secretase activity Nature 402 1999 533 537
169. L. Zhao, J.L. Wang, Y.R. Wang, and X.Z. Fa Apigenin attenuates copper-mediated β-amyloid neurotoxicity through antioxidation, mitochondrion protection and MAPK signal inactivation in an AD cell model Brain Res. 1492 2013 33 45
170. X. Zhu, X. Guo, G. Mao, Z. Gao, H. Wang, Q. He, and D. Li Hepatoprotection of berberine against hydrogen peroxide-induced apoptosis by upregulation of sirtuin 1 Phytother. Res. 27 2013 417 421